Science1 publisher2 min readPublished
One CRISPR infusion keeps LDL cholesterol roughly 50% lower for a year at the top dose
CTX310, a one-time CRISPR infusion, cut LDL by 52.5% and triglycerides by 47.8% after 12 months at its top dose in a Cleveland Clinic trial. Its 15 patients are enough to show the effect lasts but too few to rule out rare harms or to show it can replace lipid drugs.
The Scientist · Science desk
What happened
- The year-long follow-up tested whether the cholesterol and triglyceride reductions first reported two months after infusion would persist.
- CTX310 carries the CRISPR-Cas9 editing system to the liver, where it switches off ANGPTL3, a gene that helps regulate fats in the blood.
- Before the single infusion, patients were given corticosteroids and antihistamines.
- The results were presented at the 2026 European Society of Cardiology meeting and published at the same time in the New England Journal of Medicine.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- constraint A clean safety record in 15 people still allows a serious-event rate near one in five, so the safety case for a permanent liver edit has to be built in trials many times this size.
- decision Anyone weighing one-time editing against lifelong lipid drugs is working from lipid levels in patients whose disorders medication had not controlled, and that evidence cannot settle the choice for the broader population.
- cost Each participant who takes the single infusion is committed to about 16 years of safety follow-up, and sponsors of any larger CTX310 trial will have to fund that monitoring.
The highest dose was eight times the lowest. Patients received between 0.1 and 0.8 mg/kg of CTX310 [10][1]. The 12-month reductions are reported for the top dose only, measured from each patient's own baseline [3]. Cleveland Clinic's summary does not say how many of the 15 received that dose, whether anyone was given a placebo, or whether patients kept taking their existing lipid drugs [2].
"Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive," said Luke Laffin, the Cleveland Clinic cardiologist who is the study's first author [6]. I think that judgement holds for the top-dose group. The two-month data showed reductions, and the 12-month data show they were still there [2][3].
Safety is harder to judge from this sample. "It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment," Laffin said [7]. Zero in 15 is a fair result for a first-in-human study. It is also consistent with a true serious-event rate as high as about one in five. When no events turn up in n people, the upper 95% bound on the rate is roughly 3/n, and 3/15 is 20% [2]. The researchers plan another 15 years of safety follow-up, in line with FDA recommendations for gene-editing therapies [13]. With the first year included, that comes to 16 years of monitoring [3].
The patients had lipid disorders that had not responded adequately to medication [1]. Alongside safety, the trial measured ANGPTL3, LDL and triglyceride levels [12]. High LDL and triglycerides are associated with cardiovascular disease [9]. A one-year study of 15 people cannot show that lowering them this way prevents heart attacks. It was also not designed to test whether one edit can replace years of drug treatment. "We look forward to continuing to investigate this therapy in a larger number of patients," Laffin said [15].
CRISPR Therapeutics AG, of Zug, Switzerland, funded the study, and Laffin's institution has received research funding from the company [14].
What to watch
- The design of the larger CTX310 study Laffin said the team looks forward to, especially whether it has a comparison group and counts cardiovascular events.
- Any serious adverse event attributed to CTX310 during the planned 15-year safety follow-up.
- Whether the full NEJM report gives patient numbers and individual responses for each dose group.